Synageva should be bought at current levels, says RW Baird Baird said their investment thesis for Synageva remains unchanged following its successful display at the WORLD symposium last month. The firm recommends purchase at current levels as the company heads into an important value-creating period which includes potential pivotal data for a lead compound and the beginning of clinical trials for SBC-103. Shares are Outperform rated with a $107 price target.
Synageva announces submission of BLA to the FDA for sebelipase Synageva BioPharma announced the start of a rolling submission of a Biologics License Application, or BLA, to the FDA for sebelipase alfa as a treatment for patients with lysosomal acid lipase deficiency, a rare genetic disease with significant morbidity and early mortality. A rolling submission allows completed portions of the application to be submitted and reviewed by the FDA on an ongoing basis. The company anticipates completing the rolling submission of the BLA to the FDA and submitting the Marketing Authorization Application to the European Medicines Agency) by the end of January 2015.